Bayer runs into another German roadblock in marketing vision drug Eylea

Tracy Staton

Germany's cost-effectiveness watchdog said eye doesn't perform any better than its Novartis rival, Lucentis, as a treatment for diabetic macular edema.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS